# Object Record 7
**objectId:** item-1762937703769-uzlcws
**type:** dili-diagnostic
**content:** DILI Diagnostic Panel
**rotation:** 0
**diliData pattern classification:** Hepatocellular
**diliData pattern R ratio:** 15.9
**diliData pattern keyLabs 0 label:** ALT
**diliData pattern keyLabs 0 value:** 1650 U/L
**diliData pattern keyLabs 0 note:** ↑↑↑
**diliData pattern keyLabs 1 label:** AST
**diliData pattern keyLabs 1 value:** 2100 U/L
**diliData pattern keyLabs 1 note:** ↑↑↑
**diliData pattern keyLabs 2 label:** ALP
**diliData pattern keyLabs 2 value:** 350 U/L
**diliData pattern keyLabs 2 note:** ↑↑
**diliData pattern keyLabs 3 label:** Total Bilirubin
**diliData pattern keyLabs 3 value:** 12.5 mg/dL
**diliData pattern keyLabs 3 note:** ↑↑↑
**diliData pattern keyLabs 4 label:** INR
**diliData pattern keyLabs 4 value:** 1
**diliData pattern keyLabs 4 note:** Normal
**diliData pattern clinicalFeatures 0:** Severe fatigue
**diliData pattern clinicalFeatures 1:** Jaundice
**diliData pattern clinicalFeatures 2:** Epigastric pain
**diliData pattern clinicalFeatures 3:** Confusion
**diliData pattern clinicalFeatures 4:** Oral mucosal ulcerations
**diliData causality primaryDrug:** Trimethoprim-Sulfamethoxazole
**diliData causality contributingFactors 0:** Methotrexate use
**diliData causality contributingFactors 1:** Age 63
**diliData causality contributingFactors 2:** Chronic kidney disease
**diliData causality contributingFactors 3:** Alcohol use (1-2 beers/day)
**diliData causality mechanisticRationale 0:** TMP-SMX can increase free methotrexate levels.
**diliData causality mechanisticRationale 1:** TMP-SMX can impair folate metabolism.
**diliData causality mechanisticRationale 2:** Combined toxicity potentiates hepatocellular necrosis.
**diliData causality mechanisticRationale 3:** Idiosyncratic hepatocellular DILI is suggested by the timeline.
**diliData severity features 0:** Hepatic Encephalopathy (confusion, asterixis)
**diliData severity features 1:** Coagulopathy (INR 1, borderline but labs in setting of severe injury)
**diliData severity features 2:** Marked jaundice (Total Bilirubin 12.5 mg/dL)
**diliData severity features 3:** Very high transaminases (ALT 1650 U/L, AST 2100 U/L)
**diliData severity prognosis:** Severe, meets criteria for acute liver failure.
**diliData management immediateActions 0:** Withdraw Methotrexate
**diliData management immediateActions 1:** Withdraw Trimethoprim-Sulfamethoxazole
**diliData management immediateActions 2:** Initiate N-acetylcysteine
**diliData management immediateActions 3:** Admit to ICU
**diliData management immediateActions 4:** Aggressive supportive care
**diliData management consults 0:** Hepatology
**diliData management consults 1:** Gastroenterology
**diliData management consults 2:** Hematology
**diliData management monitoringPlan 0:** STAT labs including CBC, CMP, coagulation panel, Methotrexate level
**diliData management monitoringPlan 1:** Frequent neurological checks
**diliData management monitoringPlan 2:** Vital signs monitoring
**diliData management monitoringPlan 3:** Liver function tests (ALT, AST, Bilirubin, ALP) monitoring
**diliData management monitoringPlan 4:** Renal function monitoring
**createdAt:** 2025-11-12T08:55:03.775Z
**updatedAt:** 2025-11-12T08:55:03.775Z

# Object Record 5
**objectId:** dashboard-item-1759906246157-differential-diagnosis
**type:** component
**componentType:** DifferentialDiagnosis
**description:** 
**content title:** Differential Diagnosis
**content component:** DifferentialDiagnosis
**content props patientData encounters 0 encounter no:** 6
**content props patientData encounters 0 assessment impression:** Acute liver injury likely DILI and/or severe methotrexate toxicity
**content props patientData encounters 0 assessment differential 0:** Severe methotrexate toxicity (± pancytopenia, hepatic/renal injury)
**content props patientData encounters 0 assessment differential 1:** TMP-SMX–induced DILI
**content props patientData encounters 0 assessment differential 2:** Acute viral hepatitis
**content props patientData encounters 0 assessment differential 3:** Acute decompensation of undiagnosed chronic liver disease
**content props patientData encounters 0 assessment differential 4:** Sepsis with multiorgan dysfunction
**content props patientData encounters 0 rucam ctcae analysis rucam rows 0 0:** 5
**content props patientData encounters 0 rucam ctcae analysis rucam rows 0 1:** Exclusion of non-drug causes
**content props patientData encounters 0 rucam ctcae analysis rucam rows 0 2:** viral hepatitis pending
**content props patientData encounters 0 rucam ctcae analysis rucam rows 0 3:** +2
**content props patientData encounters 0 rucam ctcae analysis rucam rows 0 4:** Awaiting serology
**content props patientData encounters 0 rucam ctcae analysis reasoning:** no autoimmune or metabolic history; no fever or hemodynamic instability
**createdAt:** 2025-10-14T16:50:46.157Z
**updatedAt:** 2025-10-14T16:50:46.157Z

# Object Record 8
**objectId:** enhanced-todo-1762937977815-ua63htufs
**type:** todo
**description:** Handling query to EASL Guideline Agent in background
**todoData title:** EASL Guideline Query Workflow
**todoData description:** Handling query to EASL Guideline Agent in background
**todoData todos 0 id:** task-101
**todoData todos 0 text:** Creating question query and generating context
**todoData todos 0 status:** finished
**todoData todos 0 agent:** Data Analyst Agent
**todoData todos 0 subTodos 0 text:** Base question : What is the likely diagnosis for Sarah Miller according to EASL DILI criteria?
**todoData todos 0 subTodos 0 status:** finished
**todoData todos 0 subTodos 1 text:** Detailed Question is generated by ContextGen Agent
**todoData todos 0 subTodos 1 status:** finished
**todoData todos 1 id:** task-102
**todoData todos 1 text:** Send query to EASL Guideline Agent
**todoData todos 1 status:** finished
**todoData todos 1 agent:** Data Analyst Agent
**todoData todos 1 subTodos 0 text:** Query is processing
**todoData todos 1 subTodos 0 status:** finished
**todoData todos 1 subTodos 1 text:** Result is created in canvas
**todoData todos 1 subTodos 1 status:** finished
**rotation:** 0
**createdAt:** 2025-11-12T08:59:37.821Z
**updatedAt:** 2025-11-12T08:59:57.099Z

# Object Record 22
**objectId:** iframe-item-easl-interface
**type:** iframe
**title:** EASL Web Interface
**iframeUrl:** https://easl-board.vercel.app/
**rotation:** 0
**conversationHistory 0 id:** conv-1762938019134
**conversationHistory 0 query:** Sarah Miller, a 63-year-old female with a history of rheumatoid arthritis treated with methotrexate 20mg weekly since 2015, essential hypertension managed with lisinopril 10mg daily, and mild chronic kidney disease, presented to the emergency department with a 24-hour history of severe fatigue, jaundice, epigastric pain, and confusion six days after starting trimethoprim-sulfamethoxazole 800/160mg BID for acute bacterial sinusitis. Examination revealed jaundice, drowsiness, disorientation, asterixis, and mild epigastric tenderness. Labs showed ALT 1650 U/L, AST 2100 U/L, total bilirubin 12.5 mg/dL, and alkaline phosphatase 350 U/L. What is the likely diagnosis for Sarah Miller according to EASL DILI criteria?
**conversationHistory 0 response:** ## Medical Reasoning

**Assessing the Diagnosis Question**

I'm focused on the user's request, recognizing it as a diagnostic inquiry centered on DILI. My current line of thought involves determining how best to classify Sarah Miller's liver injury pattern (hepatocellular, cholestatic, or mixed) and correlating it with the possibility of DILI based on provided data.


**Interpreting Lab Results**

I've begun dissecting the provided lab values, specifically ALT, AST, ALP, and total bilirubin, to determine if they meet EASL DILI criteria. I've also established the assumed ULN values. Now, I'm focused on calculating the R value (ALT/ALP ratio) to classify the injury pattern and assessing if the ALT, ALP, and Bilirubin levels meet the case definitions for DILI. Next I'll check trimethoprim-sulfamethoxazole association.


**Calculating and Classifying DILI**

I've successfully determined the lab values meet the biochemical criteria for DILI, with significant elevations in ALT, ALP, and total bilirubin, exceeding EASL thresholds. The R value, calculated at 14.13, definitively establishes a hepatocellular injury pattern. Now I'm considering the patient's history and potential drug associations to refine the diagnosis and evaluate trimethoprim-sulfamethoxazole's role.


**Evaluating Next Steps**

My current focus is on a thorough review of the patient's case, incorporating all the gathered information. I'm prioritizing the established diagnosis of drug-induced liver injury (DILI) with a hepatocellular pattern, likely caused by trimethoprim-sulfamethoxazole. I'll now evaluate the severity indicators, including jaundice and encephalopathy, and determine the prognosis and how this informs the treatment considerations.


<RESPONSE>

<QUESTION>
    - Classify the question type: Diagnosis, Criteria Check
    - Identify the **clinical intent**: To determine the likely diagnosis and pattern of liver injury for Sarah Miller based on EASL DILI criteria, specifically identifying if it is drug-induced and its phenotypic classification.
    - Plan the stepsrequired to answer:
        1. Evaluate the patient's liver enzyme levels (ALT, AST, ALP, Total Bilirubin) against the Upper Limit of Normal (ULN) to confirm DILI.
        2. Calculate the ALT/ALP ratio (R value) to classify the pattern of liver injury (hepatocellular, cholestatic, or mixed) according to EASL guidelines.
        3. Identify if the implicated drug (trimethoprim-sulfamethoxazole) is known to cause DILI and its associated patterns.
        4. Consider the clinical presentation (jaundice, encephalopathy) in the context of DILI severity.- Indicate the expected "thinking intensity": minimal
</QUESTION>

<THINKING>

<PATIENT_CONTEXT>
Sarah Miller, a 63-year-old female, presents with acute liver injury symptoms including severe fatigue, jaundice, epigastric pain, and confusion, six days after initiatingtrimethoprim-sulfamethoxazole. Her laboratory results show significantly elevated liver enzymes (ALT 1650 U/L, AST 2100 U/L) and total bilirubin (12.5 mg/dL), with a moderately elevated alkaline phosphatase (350 U/L).Clinically, she exhibits jaundice, drowsiness, disorientation, and asterixis, indicating hepatic encephalopathy. While specific thresholds for ALBI, APRI, HVPG, CSPH, ICG-R15, INR, MELD, PHLF Risk, and Milan Criteria are not directly applicable for DILI diagnosis,her current presentation of acute liver failure with encephalopathy and jaundice suggests a severe clinical picture, which would typically correlate with poor liver function and increased risk of adverse outcomes if this were a chronic liver disease context. The acute onset and clear temporal relationship to a new medication are key anchors for DILI assessment.
</PATIENT_CONTEXT><CONVERGENT>
The clinical intent is to classify Sarah Miller's liver injury according to EASL DILI criteria.

To classify the pattern of liver injury, the EASL guidelines define DILI based on specific biochemical thresholds and patterns. Sarah Miller's lab values show ALT 1650 U/L, AST 2100 U/L, total bilirubin 12.5 mg/dL, and alkaline phosphatase (ALP) 350 U/L. Assuming standard Upper Limit of Normal (ULN) values (e.g., ALT ~40 U/L, ALP ~120 U/L, TBL ~1.2 mg/dL), her ALT is >41 times ULN, ALP is ~2.9 times ULN, and TBL is >10 times ULN.

The EASL criteria for DILI include: i) ≥5 ULN elevationin ALT, ii) ≥2 ULN elevation in ALP, or iii) ≥3 ULN elevation in ALT and simultaneous elevation of TBL concentration exceeding 2 ULN [cite: DILI_26_Patterns_o, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. Sarah meets all three criteria: her ALT is significantly >5 ULN, her ALP is >2 ULN, and she has both ALT >3 ULN and TBL >2 ULN. This confirms a biochemical diagnosis of DILI.

To determine the pattern of injury, the ratio of serum activity of ALT toALP (R value) is calculated, where R = (ALT activity / ULN) / (ALP activity / ULN) [cite: DILI_26_Patterns_o, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. Using the approximateULN values, R = (1650/40) / (350/120) = 41.25 / 2.92 ≈ 14.13.
According to EASL guidelines, a hepatocellular pattern is defined if ALT alone is elevated ≥5-fold above ULN or R ≥5 [cite: DILI_26_Patterns_o, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. Since Sarah's R value is 14.13 (which is ≥5), herliver injury is classified as hepatocellular.

Furthermore, trimethoprim-sulfamethoxazole (co-trimoxazole) is explicitly listed as an antimicrobial associated with idiosyncratic DILI, specifically under the hepatocellular pattern [cite: DILI_26_Patterns_o, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. The patient's symptoms, including jaundice and confusion (encephalopathy), indicate severe liver injury. The guidelines state that "Elevated aminotransferases in conjunction with jaundice, however, are well-known to reflect a higher risk of a severe outcome" [cite: DILI_50_Prognosis_, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. The rapid onset of severe symptoms six days after starting the medication is consistent with idiosyncratic DILI.
</CONVERGENT>

<LOCAL_CONVERGENT>
The localguidelines provided do not contain specific criteria for the diagnosis or classification of drug-induced liver injury (DILI) patterns. They focus on management aspects of specific liver conditions (autoimmune liver disease, alcohol-related liver disease, ascites, liver ablation) or general patient information regarding medications like tacrolimus. Therefore,a direct application of local guidelines for DILI diagnosis and pattern classification is not possible in this context.
</LOCAL_CONVERGENT>

<GAP_ANALYSIS>
- **Concordance**: There is no direct concordance as the local guidelines do not address the specific diagnostic criteria for DILI or its classification patterns.
- **Divergence**: No direct divergence can be identified as the local guidelines do not provide comparable diagnostic criteria for DILI.
- **Gaps & Alternatives**: The local guidelines lack specific information on DILI diagnosis, classification, and management, which is comprehensively covered by the EASL guidelines. The localguidelines focus on patient information for specific treatments (tacrolimus, liver ablation) and conditions (alcohol-related liver disease, ascites).
- **Resolution Strategy**: In the absence of local guidelines for DILI diagnosis and classification, the comprehensive EASL guidelines should be followed as the primary source for determining the likely diagnosis and patternof liver injury.
</GAP_ANALYSIS>

<RISK_ANALYSIS>
For Sarah Miller, the primary risk is severe drug-induced liver injury (DILI) leading to acute liver failure, as evidenced by jaundice and encephalopathy (confusion, drowsiness, asterixis). The implicated drug, trimethoprim-sulfamethoxazole, is a known cause of idiosyncratic DILI. The rapid onset of severe symptoms within six days of starting the medication highlights the acute and potentially life-threatening nature of this adverse drug reaction. The presence of encephalopathy and jaundice indicates a severe outcome, which, according to EASL guidelines, carriesa mortality/liver transplant rate exceeding 10% in hepatocellular damage with jaundice [cite: DILI_50_Prognosis_, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. Her history of rheumatoid arthritis treated with methotrexate and mild chronic kidney disease could potentially influenceher susceptibility or the severity of DILI, although the primary driver here appears to be the trimethoprim-sulfamethoxazole.
</RISK_ANALYSIS>

</THINKING>



## Answer


<short_answer>
Based on EASL DILI criteria, Sarah Miller's presentation is consistent with a severe hepatocellular pattern of drug-induced liver injury (DILI), most likely caused by trimethoprim-sulfamethoxazole. This diagnosis is supported by significant elevations in ALT and AST, an ALT/ALP ratio greater than 5, and the presence of jaundice and encephalopathy, indicating ahigh risk of severe outcome.
</short_answer>

<detailed_answer>
Sarah Miller's clinical picture and laboratory findings strongly indicate a severe hepatocellular pattern of drug-induced liver injury (DILI) according to EASL guidelines. Her ALT (1650 U/L) is more than 41 times theUpper Limit of Normal (ULN), and her total bilirubin (12.5 mg/dL) is more than 10 times ULN. The EASL criteria for DILI are met as her ALT is ≥5 ULN, and she has both ALT ≥3 ULN and total bilirubin >2 ULN [cite:DILI_26_Patterns_o, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf].

To classify the pattern of injury, the ratio of ALT to ALP activity (R value) is calculated. With an estimated R value of approximately 14.13 (basedon ALT 1650 U/L and ALP 350 U/L, assuming standard ULNs), which is significantly greater than 5, the injury is definitively classified as hepatocellular [cite: DILI_26_Patterns_o, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. Trimethoprim-sulfamethoxazole (co-trimoxazole), which Sarah started six days prior to symptom onset, is a known antimicrobial associated with idiosyncratic DILI, specifically presenting with a hepatocellular pattern [cite: DILI_26_Patterns_o, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf]. The presence of jaundice, drowsiness, disorientation, and asterixis signifies severe liver injury with encephalopathy, a condition known to carry a higher risk of severe outcomes, including mortality or the need for liver transplantation [cite: DILI_50_Prognosis_, p.1, https://storage.googleapis.com/easl-pdf/DILI.pdf].
</detailed_answer>

<GAP_SUMMARY>
The EASL guidelines provide comprehensive diagnostic criteria and classification for drug-induced liver injury (DILI), which were directly applied to Sarah Miller's case. The local guidelines provided do not contain specific information or criteria for DILI diagnosis or classification patterns, focusing instead on general patient information for specific liver conditions or treatments. Therefore, there is a gap in local guidance regarding DILI diagnosis, and the EASL guidelines serveas the primary and most relevant source for this clinical scenario.
</GAP_SUMMARY>
<LOCAL_GUIDELINE_LIST>
{
    "local_guidelines": [
        {
            "name": "Tacrolimus for the treatment of autoimmune liver disease"
        },
        {"name": "Alcohol and the Liver"
        },
        {
            "name": "Information leaflet for patients with ascites in advanced liver disease needing an indwelling (Rocket) peritoneal catheter"
        },
        {
            "name": "Liver ablation - A guide for patients"}
    ]
}
</LOCAL_GUIDELINE_LIST>
<guideline_references>
{
"Source": "EASL Clinical Practice Guidelines: Drug-induced liver injury-Patterns of DILI",
"Link": "https://storage.googleapis.com/easl-pdf/DILI.pdf",
"Supporting": "Case definitions for DILI include one of the following thresholds: i) ≥5 ULN elevation in ALT, ii) ≥2 ULN elevation in ALP... or iii) ≥3 ULN elevation in ALT and simultaneous elevation of TBL concentration exceeding 2 ULN. ... Liver injury is designated ‘hepatocellular’ when there is a 5-fold or higher rise in ALT alone or when the ratio of serum activity (activity is expressed as a multiple of ULN) of ALT to ALP is 5 or more. ... Table 3. Definitions, phenotypes and drugs associated with hepatic adverse reactions. ... Antimicrobials: ...co-trimoxazole, sulfonamides."
},
{
"Source": "EASL Clinical Practice Guidelines: Drug-induced liver injury-Prognosis and Natural History: Grading Severity",
"Link": "https://storage.googleapis.com/easl-pdf/DILI.pdf",
"Supporting": "Elevated aminotransferases in conjunction with jaundice, however, are well-known to reflect a higher risk of a severe outcome. ... patients with hepatocellular damage and jaundice have a mortality/liver transplant rate exceeding 10%."
}
</guideline_references>

**conversationHistory 0 timestamp:** 2025-11-12T09:00:19.134Z
**conversationHistory 0 metadata chatId:** MZltPRypDHMIAXU3x2Vq
**conversationHistory 0 metadata messageId:** ai-75249a04-5e70-414f-b269-56f7d0571435
**conversationHistory 0 metadata expertName:** General Liver Disease Expert
**conversationHistory 0 metadata source:** easl-chat
**conversationHistory 0 metadata hasReasoning:** True
**conversationHistory 0 metadata hasSafetyAnalysis:** True
**conversationHistory 0 metadata hasLocalGuidelineAnalysis:** False
**conversationHistory 0 metadata timestamp:** 2025-11-12T09:00:16.821Z
**conversationHistory 0 response type:** complete
**createdAt:** 2025-10-28T12:00:00.000Z
**updatedAt:** 2025-11-12T09:00:19.134Z

# Object Record 5
**objectId:** dashboard-item-1759906300004-single-encounter-6
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #6 - Emergency Visit
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 6
**content props encounter meta visit type:** ED
**content props encounter meta date time:** 2025-06-21T14:00:00
**content props encounter meta provider name:** Dr. Sarah Chen
**content props encounter meta provider specialty:** Emergency Medicine
**content props encounter meta ui risk color:** red
**content props encounter meta event tags 0:** Suspected DILI
**content props encounter meta event tags 1:** Potential MTX toxicity
**content props encounter meta event tags 2:** Acute liver failure risk
**content props encounter reason for visit:** Severe fatigue, jaundice, epigastric pain, confusion
**content props encounter chief complaint:** Severe fatigue, jaundice, epigastric pain, confusion
**content props encounter hpi:** 63-year-old female with 24h severe fatigue, jaundice, epigastric pain; 4–6 days prior noted fatigue, mouth ulcers, nausea; started TMP-SMX 6 days ago for sinusitis
**content props encounter medications prior 0 name:** Methotrexate
**content props encounter medications prior 0 dose:** 20 mg
**content props encounter medications prior 0 route:** PO
**content props encounter medications prior 0 frequency:** weekly
**content props encounter medications prior 1 name:** Trimethoprim-Sulfamethoxazole
**content props encounter medications prior 1 dose:** 800/160 mg
**content props encounter medications prior 1 route:** PO
**content props encounter medications prior 1 frequency:** BID
**content props encounter physical exam general:** Jaundiced, fatigued, drowsy; disoriented to time/place
**content props encounter physical exam abdomen:** Soft, non-distended; mild epigastric tenderness
**content props encounter physical exam cns:** Arousable; PERL; slow commands; asterixis present; GCS 13
**content props encounter assessment impression:** Acute liver injury likely DILI and/or severe methotrexate toxicity
**content props encounter assessment differential 0:** Severe methotrexate toxicity
**content props encounter assessment differential 1:** TMP-SMX–induced DILI
**content props encounter assessment differential 2:** Acute viral hepatitis
**content props encounter plan investigations labs 0:** CBC
**content props encounter plan investigations labs 1:** CMP
**content props encounter plan investigations labs 2:** Methotrexate level (urgent)
**content props encounter plan investigations labs 3:** HAV IgM
**content props encounter plan investigations labs 4:** HBsAg
**content props encounter plan management education 0:** Immediate ICU admission
**content props encounter plan management education 1:** N-acetylcysteine protocol
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 53
**content props encounterIndex:** 5
**content props dataSource:** VueExplore
**createdAt:** 2025-10-14T16:55:00.004Z
**updatedAt:** 2025-10-14T16:55:00.004Z

# Object Record 13
**objectId:** raw-viper-ultrasound-ivc
**type:** component
**componentType:** RawClinicalNote
**description:** Raw Viper ultrasound IVC assessment
**content title:** Viper - IVC Ultrasound
**content component:** RawClinicalNote
**content props encounterNumber:** 0
**content props date:** 2025-06-21
**content props visitType:** IVC Ultrasound (Point-of-Care)
**content props provider:** Dr. Sarah Chen
**content props specialty:** Emergency Medicine
**content props rawText:** VIPER Ultrasound (ICU/ED Point-of-Care)
Date/Time: 2025-06-21 15:30 (ED/ICU).
Operator: Dr. Sarah Chen (Emergency Medicine).
Procedure: Ultrasound of Inferior Vena Cava (IVC) – Subxiphoid long-axis.
Findings (VIPER quantitative analysis):
IVC diameter on inspiration: 2.0 cm
IVC diameter on expiration: 2.3 cm
IVC Collapsibility Index: 13% (insp/exp variation)
Interpretation: IVC minimally collapsible; suggests normal to increased intravascular volume. No significant hypovolemia.
Clinical Use: Results used to guide fluid management. (In this case, moderate fluids given carefully as patient shows probable volume repletion.)
(VIPER’s automated analysis provides objective IVC measurements and a quick interpretation to optimize fluid therapy decisions.)

**content props dataSource:** VIPER Ultrasound
**createdAt:** 2025-10-17T03:49:53.778Z
**updatedAt:** 2025-10-17T03:49:53.779Z